Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**EVerGel** is an investigational, locally delivered regenerative therapy developed for digestive-tissue healing. It consists of naïve exosomes derived from human adipose stem cells embedded in a thermoresponsive hydrogel; the liquid gel is injected at the injury site and undergoes in situ gelation at body temperature to improve local exosome retention and controlled release. Its lead indication is complex perianal fistula associated with Crohn's disease, with additional development interest in digestive anastomotic healing, stenosis, and postoperative adhesions. EVerGel has generated preclinical in vitro and in vivo proof-of-concept data and is intended for clinical development. ([everzom.com](https://everzom.com/therapeutic-programs/evergel/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EVerGel.